Services
Three ways we improve acquisition economics.
Channel work and funnel work are the same job. We do both, and we hold both to the downstream outcome that determines whether acquisition pays back. Programmatic display, native, and other channels sit inside the mix where the math supports them.
Capabilities
Buy the media, qualify what it produces, measure far enough down.
Each of these can be run on its own. They work considerably better together, because the third is what tells you whether the first two are working.
Channel coverage
Programmatic, and everything else that pays back.
Programmatic display, native, and CTV sit inside the channel mix rather than on their own page. They earn budget on the same terms as everything else: a payback threshold agreed up front and a read on cost per qualified lead before they scale.
We would rather concentrate spend in the one or two channels that work for your patient journey, geographies, and economics than present a broad media mix for its own sake. Which channels those turn out to be is an output of the economic model in step one, not a preference we bring to the first call.
FAQ
The questions healthcare teams actually ask.
Enrollment economics. Cost per lead is a checkpoint, not the goal. In clinical-trial recruitment we reconcile screening and enrollment outcomes back to source; in other healthcare models the equivalent may be a qualified patient, booked visit, completed consultation, treatment start, or another downstream outcome that actually determines the economics.
Through whatever approved system can provide it — EHR or CRM exports, booking status, CTMS data, referral outcomes, call-center dispositions, or even a simple weekly reconciliation. We use the lightest-weight pipeline that still lets acquisition decisions reflect real downstream outcomes.
A standing weekly view of spend, qualification, and the early downstream signals available by channel and campaign, plus a deeper periodic review that reconciles against business or clinical outcomes. Reporting should use the terms your operation already uses rather than forcing the business to translate an ad-platform dashboard.
We recommend cutting it. Every channel is launched with an economic threshold agreed up front, which makes that call a documented decision rather than an argument. We would rather concentrate budget in the channels that work than defend a broad media mix for its own sake.
Our core strength is performance marketing — paid social, search, and programmatic — combined with qualification and downstream measurement. Our current specialty positioning includes clinical-trial recruitment and virtual care. The model travels across therapeutic areas because the discipline is the same: buy on unit economics, screen hard, and optimize to the outcome that actually funds the program.
Yes, and we plan for it from the first test rather than discovering it later. Creative concepts are drafted to fit the language and materials your IRB or ethics-review process requires, submissions are batched so approval is not a per-asset bottleneck, and the test matrix is built to still be readable within the set of variants you are permitted to run.
Next step
Tell us what you're trying to acquire.
Show us where patients come from, what qualifies, what happens after the lead, and the economics you need to hit. We'll tell you honestly whether we're the right partner.